Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP, Latupeirissa K, Schetters S, van Kooyk Y, Boon L, Moyaart A, Mueller YM, Katsikis PD, Eggermont AM, Vroman H, Stadhouders R, Hendriks RW, Thüsen JV, Grünhagen DJ, Verhoef C, van Hall T, Aerts JG. Dammeijer F, et al. Among authors: van den bosch t, van hall t, van gulijk m, van nimwegen m, van kooyk y. Cancer Cell. 2020 Nov 9;38(5):685-700.e8. doi: 10.1016/j.ccell.2020.09.001. Epub 2020 Oct 1. Cancer Cell. 2020. PMID: 33007259 Free article.
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG. Dammeijer F, et al. Among authors: van hall t, van nimwegen m. Cancer Immunol Res. 2017 Jul;5(7):535-546. doi: 10.1158/2326-6066.CIR-16-0309. Epub 2017 May 23. Cancer Immunol Res. 2017. PMID: 28536100
FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.
Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS. Sow HS, et al. Among authors: van hall t. Int J Cancer. 2019 Jan 15;144(2):345-354. doi: 10.1002/ijc.31899. Epub 2018 Nov 12. Int J Cancer. 2019. PMID: 30259976 Free article.
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F. Fransen MF, et al. Among authors: van hall t. JCI Insight. 2018 Dec 6;3(23):e124507. doi: 10.1172/jci.insight.124507. JCI Insight. 2018. PMID: 30518694 Free PMC article.
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E. van Hall T, et al. Among authors: van der burg sh. J Immunother Cancer. 2019 Oct 17;7(1):263. doi: 10.1186/s40425-019-0761-3. J Immunother Cancer. 2019. PMID: 31623687 Free PMC article. Review.
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
Lau SP, van Montfoort N, Kinderman P, Lukkes M, Klaase L, van Nimwegen M, van Gulijk M, Dumas J, Mustafa DAM, Lievense SLA, Groeneveldt C, Stadhouders R, Li Y, Stubbs A, Marijt KA, Vroman H, van der Burg SH, Aerts J, van Hall T, Dammeijer F, van Eijck CHJ. Lau SP, et al. Among authors: van hall t, van der burg sh, van gulijk m, van montfoort n, van nimwegen m, van eijck chj. J Immunother Cancer. 2020 Jul;8(2):e000772. doi: 10.1136/jitc-2020-000772. J Immunother Cancer. 2020. PMID: 32690771 Free PMC article.
Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function.
Beyranvand Nejad E, Labrie C, van der Sluis TC, van Duikeren S, Franken KLMC, Roosenhoff R, Arens R, van Hall T, van der Burg SH. Beyranvand Nejad E, et al. Among authors: van duikeren s, van hall t, van der burg sh, van der sluis tc. Int J Cancer. 2021 Jan 1;148(1):211-225. doi: 10.1002/ijc.33280. Epub 2020 Sep 7. Int J Cancer. 2021. PMID: 32875568 Free PMC article.
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C, Kinderman P, van den Wollenberg DJM, van den Oever RL, Middelburg J, Mustafa DAM, Hoeben RC, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van den oever rl, van hall t, van der burg sh, van montfoort n, van den wollenberg djm. J Immunother Cancer. 2020 Oct;8(2):e001191. doi: 10.1136/jitc-2020-001191. J Immunother Cancer. 2020. PMID: 33082167 Free PMC article.
122 results